 CAMBRIDGE, Ma., Nov. 16, 2020 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. Trillium or the Company NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the nine months ended September 30, 2020. 